Elicera Therapeutics (Q3 Review): Entering a Catalyst-Dense Phase - Redeye

Redeye returns with an update following Elicera’s Q3 earnings release. The numbers offered few surprises, which is typical for a pre-revenue biotech. What stands out is the busy period ahead, with two clinical data readouts expected over the next five months.

Länk till analysen i sin helhet: https://www.redeye.se/research/1139444/elicera-therapeutics-q3-review-entering-a-catalyst-dense-phase?utm_source=finwire&utm_medium=RSS